Comparison of visual criteria for amyloid-PET reading: could criteria merging reduce inter-rater variability?


Journal

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
ISSN: 1827-1936
Titre abrégé: Q J Nucl Med Mol Imaging
Pays: Italy
ID NLM: 101213861

Informations de publication

Date de publication:
Dec 2020
Historique:
pubmed: 16 5 2019
medline: 8 9 2021
entrez: 16 5 2019
Statut: ppublish

Résumé

Three different amyloid tracers labeled with 18-flourine have been introduced into clinical use. The leaflets of tracers indicate different visual criteria for PET reporting. In clinical practice, it is not yet ascertained whether these criteria are equivalent in terms of diagnostic accuracy or if anyone is better than another. We aimed to evaluate the inter and intra-rater variability of visual assessment of We analyzed 252 PET/CT scans, visually assessed by each reader three times, applying independently the three different reading criteria proposed. Each reader evaluated the regional uptake specifying for each cortical region a numeric value of grading of positivity in order to assign a final score. At the end of each reading a level of confidence was determined by assigning a score from 0 (negative) to 4 (positive). After first reading, those cases in which the evaluations by two experienced readers did not match (discordant cases) were independently reevaluated merging all the three different visual interpretation criteria. Good agreement was observed for visual interpretation among the six readers' confidence-level using independently the three visual reading criteria: ICC=0.83 (0.80-0.86) for All the criteria proposed are useful to determine the grading of positivity or negativity of amyloid deposition and their merging improves the diagnostic confidence and provides a better agreement.

Sections du résumé

BACKGROUND BACKGROUND
Three different amyloid tracers labeled with 18-flourine have been introduced into clinical use. The leaflets of tracers indicate different visual criteria for PET reporting. In clinical practice, it is not yet ascertained whether these criteria are equivalent in terms of diagnostic accuracy or if anyone is better than another. We aimed to evaluate the inter and intra-rater variability of visual assessment of
METHODS METHODS
We analyzed 252 PET/CT scans, visually assessed by each reader three times, applying independently the three different reading criteria proposed. Each reader evaluated the regional uptake specifying for each cortical region a numeric value of grading of positivity in order to assign a final score. At the end of each reading a level of confidence was determined by assigning a score from 0 (negative) to 4 (positive). After first reading, those cases in which the evaluations by two experienced readers did not match (discordant cases) were independently reevaluated merging all the three different visual interpretation criteria.
RESULTS RESULTS
Good agreement was observed for visual interpretation among the six readers' confidence-level using independently the three visual reading criteria: ICC=0.83 (0.80-0.86) for
CONCLUSIONS CONCLUSIONS
All the criteria proposed are useful to determine the grading of positivity or negativity of amyloid deposition and their merging improves the diagnostic confidence and provides a better agreement.

Identifiants

pubmed: 31089074
pii: S1824-4785.19.03124-8
doi: 10.23736/S1824-4785.19.03124-8
doi:

Substances chimiques

Amyloid 0
Aniline Compounds 0
Benzothiazoles 0
Ethylene Glycols 0
Fluorine Radioisotopes 0
Stilbenes 0
flutemetamol 0F3M7032P5
florbetapir 6867Q6IKOD
Fluorine-18 GZ5I74KB8G
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene TLA7312TOI

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

414-421

Auteurs

Barbara Paghera (B)

Department of Nuclear Medicine, University of Brescia, Brescia, Italy - barbara.paghera@asst-spedalicivili.it.

Daniele Altomare (D)

Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), San Giovanni di Dio Clinical Research Center, Brescia, Italy.
Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Alessia Peli (A)

Department of Nuclear Medicine, University of Brescia, Brescia, Italy.

Silvia Morbelli (S)

Department of Nuclear Medicine, San Martino University Hospital and IRCCS, Genoa, Italy.

Ambra Buschiazzo (A)

Department of Nuclear Medicine, San Martino University Hospital and IRCCS, Genoa, Italy.

Matteo Bauckneht (M)

Department of Nuclear Medicine, San Martino University Hospital and IRCCS, Genoa, Italy.

Raffaele Giubbini (R)

Department of Nuclear Medicine, University of Brescia, Brescia, Italy.

Carlo Rodella (C)

Department of Nuclear Medicine, University of Brescia, Brescia, Italy.

Luca Camoni (L)

Department of Nuclear Medicine, University of Brescia, Brescia, Italy.

Marina Boccardi (M)

Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), San Giovanni di Dio Clinical Research Center, Brescia, Italy.
Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.

Cristina Festari (C)

Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), San Giovanni di Dio Clinical Research Center, Brescia, Italy.
Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Cristina Muscio (C)

Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), San Giovanni di Dio Clinical Research Center, Brescia, Italy.
Division of Neurology V - Neuropathology, Carlo Besta Institute of Neurology Foundation and IRCCS, Milan, Italy.

Alessandro Padovani (A)

Unit of Neurology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Giovanni B Frisoni (GB)

Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), San Giovanni di Dio Clinical Research Center, Brescia, Italy.
Department of Nuclear Medicine, San Martino University Hospital and IRCCS, Genoa, Italy.
Memory Clinic, University Hospital of Geneva, Geneva, Switzerland.

Ugo P Guerra (UP)

Department of Nuclear Medicine, Poliambulanza Foundation, Brescia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH